Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, South Korea.
J Ocul Pharmacol Ther. 2020 Nov;36(9):703-710. doi: 10.1089/jop.2019.0158. Epub 2020 Jun 17.
To evaluate the periodicity of the intervals of lesion reactivation in patients with neovascular age-related macular degeneration (AMD). This retrospective study included 139 eyes diagnosed with treatment-naive neovascular AMD and treated with antivascular endothelial growth factor (VEGF) therapy. Patients were initially treated with 3 loading anti-VEGF injections using either ranibizumab or aflibercept. Additional treatment was administered only when lesion reactivation was noted. The difference between the time intervals to the first and the second reactivations was evaluated. The included eyes were divided into 2 groups according to the time interval to the first reactivation: the early reactivation group (≤6 months, = 86) and the late reactivation group (>6 months, = 53). The association between the time intervals to the first and the second reactivations was evaluated within each group. The mean follow-up period was 52.7 ± 8.9 months. The first reactivation was noted at mean 9.4 ± 10.4 months after the loading injections. The second reactivation was noted at mean 6.2 ± 4.9 months after the treatment for the first reactivation. The time interval to the second reactivation was significantly shorter compared with the first reactivation ( = 0.018). The association between the time interval to the first and the second reactivations was significant only in the early reactivation group ( = 0.002). A short first reactivation interval suggests that there is a high likelihood that the second reactivation will also be short. However, a long first reactivation interval does not suggest that the second reactivation interval will be similarly long.
评估新生血管性年龄相关性黄斑变性（AMD）患者病变再激活间隔的周期性。这项回顾性研究纳入了 139 只诊断为新生血管性 AMD 且接受抗血管内皮生长因子（VEGF）治疗的未经治疗的患眼。患者最初接受 3 次负荷剂量抗 VEGF 注射，药物分别为雷珠单抗或阿柏西普。仅当病变再激活时才给予额外治疗。评估首次和第二次再激活之间的时间间隔差异。根据首次再激活的时间间隔，将纳入的患眼分为两组：早期再激活组（≤6 个月，=86）和晚期再激活组（>6 个月，=53）。评估每组内首次和第二次再激活之间的时间间隔的相关性。平均随访时间为 52.7±8.9 个月。首次再激活发生在负荷剂量注射后平均 9.4±10.4 个月。第二次再激活发生在首次再激活治疗后平均 6.2±4.9 个月。与首次再激活相比，第二次再激活的时间间隔明显缩短（=0.018）。首次和第二次再激活之间的时间间隔相关性仅在早期再激活组中显著（=0.002）。首次再激活间隔较短提示第二次再激活也很可能较短。然而，首次再激活间隔较长并不提示第二次再激活间隔也会同样长。
